Viropro Stock

Viropro ROE

The Return on Equity (ROE) of Viropro (VPRO) as of Aug 17, 2026 is -69.36 %.

ROE

-69.36 %

Last updated:

In 2026, Viropro's return on equity (ROE) was -69.36 %, a % increase from the - ROE in the previous year.

Access this data via the Eulerpool API

Viropro Stock analysis

What does Viropro do? Viropro Inc. is a pharmaceutical company specializing in the use of technologies for the production of biopharmaceutical products. Founded in 2004, the company aims to develop innovative and effective solutions for medical niche areas. The company is based in Canada and also has locations in Europe and Asia. With over 100 employees worldwide, Viropro offers a wide range of laboratory services to develop effective and safe medications. Viropro relies on a unique business model that utilizes cell culture technologies and bioreactors. They utilize a highly specialized cell preparation technology called "VIPER" which ensures the production of recombinant proteins and antibodies of the highest quality. Partnerships with other pharmaceutical and biotechnology companies are also an important aspect of Viropro's business model. They work with many companies to develop and bring medications to the market. Viropro's business activities extend to several areas within the bioproduct sector. However, the core element is the antibodies that the company produces and markets. Viropro's products also include human antibodies against cancer, HIV, and other serious diseases. Their portfolio also includes pharmacokinetic studies, antigen and peptide design services, as well as cell preparation and culture processing services. With a wide range of services and products, the company is able to develop customized solutions for the specific needs of its customers. In the field of cell preparation, Viropro primarily offers laboratory services that include a wide range of equipment and associated technologies. The VIPER technology developed by Viropro is a core component of this business unit. The peptide and antigen design unit offers services that focus on the identification and optimization of antibodies and peptides. The latest computer-based methods are used to simulate how certain proteins can develop on the computer. These methods are particularly effective in developing antibody-based medications. Finally, Viropro also offers pharmacokinetic services to ensure the safety and effectiveness of medications, as well as proper administration and dosage. Although the company is still relatively young, Viropro already has an impressive track record in the development and marketing of bioproducts. The company has brought several antibodies to the market and is contributing to providing lifesaving therapies for some of the most serious health problems of our time. Overall, Viropro is an exciting biotechnology company operating in a rapidly growing market and tackling some of the most important therapeutic challenges of our time. With the combination of innovative technologies and a flexible business model, the company is well-positioned to continue playing a leading role in the pharmaceutical and biotechnology industry. Viropro is one of the most popular companies on Eulerpool.

ROE Details

Decoding Viropro's Return on Equity (ROE)

Viropro's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Viropro's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Viropro's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Viropro’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Viropro stock

Return on Equity (ROE) of Viropro is -69.36 % in 2026.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Viropro since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Viropro with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Viropro

All Key Metrics — Viropro